These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38787395)

  • 1. Development and evaluation of albumin binder-conjugated heterodimeric radiopharmaceuticals targeting integrin α
    Yang B; Shan C; Song X; Lv X; Long Y; Zeng D; An R; Lan X; Gai Y
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3334-3345. PubMed ID: 38787395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an Integrin α
    Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
    Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of a dual-receptor targeted tracer [
    Lv X; Song X; Long Y; Zeng D; Lan X; Gai Y
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):54-67. PubMed ID: 37642706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
    J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of
    Ganguly T; Bauer N; Davis RA; Foster CC; Harris RE; Hausner SH; Roncali E; Tang SY; Sutcliffe JL
    J Nucl Med; 2023 Apr; 64(4):639-644. PubMed ID: 36207137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin α
    Liu K; Jiang T; Rao W; Chen B; Yin X; Xu P; Hu S
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1544-1557. PubMed ID: 38276986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, preclinical, and initial clinical evaluation of integrin α
    Wen X; Wang R; Xu P; Shi M; Shang Q; Zeng X; Zeng X; Liu J; Wang X; Zhu Z; Guo Z; Chen X; Zhang J
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2023-2035. PubMed ID: 38376806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of [
    Liu N; Wan Q; Wu X; Zhao T; Jakobsson V; Yuan H; Chen X; Zhang J; Zhang W
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1685-1697. PubMed ID: 38246909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Characterization of 4
    Lobeek D; Franssen GM; Ma MT; Wester HJ; Decristoforo C; Oyen WJG; Boerman OC; Terry SYA; Rijpkema M
    J Nucl Med; 2018 Aug; 59(8):1296-1301. PubMed ID: 29626124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
    Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
    Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin.
    Notni J; Steiger K; Hoffmann F; Reich D; Kapp TG; Rechenmacher F; Neubauer S; Kessler H; Wester HJ
    J Nucl Med; 2016 Mar; 57(3):460-6. PubMed ID: 26635338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Copper-64-Labeled α
    Ganguly T; Bauer N; Davis RA; Hausner SH; Tang SY; Sutcliffe JL
    Mol Pharm; 2021 Dec; 18(12):4437-4447. PubMed ID: 34783573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
    Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
    Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
    Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging.
    Liu Z; Niu G; Shi J; Liu S; Wang F; Liu S; Chen X
    Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):947-57. PubMed ID: 19159928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of
    Fonseca Cabrera GO; Ma X; Lin W; Zhang T; Zhao W; Pan L; Li X; Barnhart TE; Aluicio-Sarduy E; Deng H; Wu X; Rakesh KP; Li Z; Engle JW; Wu Z
    J Nucl Med; 2024 Aug; 65(8):1250-1256. PubMed ID: 38871388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
    Liu Z; Yan Y; Liu S; Wang F; Chen X
    Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.